Contracts › 75N93023C00052
75N93023C00052: To Conduct Clinical Development of a Compound for the Treatment of Covid-19.
Awarded to Aligos Therapeutics Inc by National Institutes of Health (NIH).
$11.3Mobligated
$11.3Mpotential value
31 December 2026current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N93023C00052 |
|---|---|
| Awardee | Aligos Therapeutics Inc |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | CA |
| Offers received | 7 |
| Period of performance | 22 September 2023 to 31 December 2026 |
| Potential end | 31 December 2026 |
| Estimated recompete solicitation | Now / imminent (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record